Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer ( 6%) larynx (52%/36%) subcutaneoustis...)

Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

6%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), lung (11%/8%), spinal cord (4%/3%), and bone (4%/5%) in the ERBITUX and radiation versus radiation alone arms, respectively.

The incidence of Grade 3 or 4 late radiation toxicities were generally similar between the radiation therapy alone and the ERBITUX plus radiation therapy arms.

The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in
'"/>

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer

Post Your Comments:

(Date:12/16/2009)... NASHVILLE, Tenn. , Dec. 16 ... medical cost management services, today commended two new ... from CT scans and other diagnostic imaging tests. ... essential to proper diagnosis and treatment," said Gregg ... these new studies offer more compelling evidence that ...

(Date:12/16/2009)... -- Wound Management Technologies, Inc. (OTC Bulletin ... specialty medical products, announced today that its ... productization of its patented orthopedic bone void ... to be introduced in Q3 2010, to ... multi-billion dollar international market. ,, "Resorbable Orthopedics ...

(Date:12/16/2009)... A new application developed ... clinical review of specialty pharmaceuticals has increased health ... reviewed while reducing costs. ,, AIM, a leading ... health plan clients representing over 35 million consumers ... WLP ), adapted the successful clinical ...

Breaking Medicine Technology:MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2 MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3 Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2 Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4 NCR Embeds DigitalPersona U are U 28R 29 4500HD Fingerprint Sensor in New NCR RealPOS 28TM 29 70XRT Point of Sale Workstations 10017 1 NCR Embeds DigitalPersona U are U 28R 29 4500HD Fingerprint Sensor in New NCR RealPOS 28TM 29 70XRT Point of Sale Workstations 10017 2 45 000 excess deaths annually linked to lack of health insurance 3A Harvard study 57890 1 45 000 excess deaths annually linked to lack of health insurance 3A Harvard study 57890 2 Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 1 Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 2 Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 3 Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 4

[0] MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure [0] Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics [0] American Imaging Management's New Specialty Drug Program Delivers Immediate Results

... Diabetes Therapy Also Improved Glucose ... Day, SAN FRANCISCO, June 9 Amylin Pharmaceuticals,Inc. ... LLY ), and Alkermes, Inc.,(Nasdaq: ALKS ) ... showed the durable efficacy of exenatide once weekly, a,long-acting ...

... long-term, large-scale and,independent studies evaluating cardiovascular (CV) outcomes ... 9,300 patients taking AVANDIA(R),(rosiglitazone maleate) and provide more ... The Veterans Affairs Diabetes Trial,(VADT), through two separate ... is no evidence to suggest that use of ...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)

(Date:12/16/2009)... to disease , , WEDNESDAY, Dec. 16 (HealthDay News) ... leprosy have been identified by scientists in Singapore ... than 10,000 DNA samples from leprosy patients and ... the important role that the innate immune response ... leprosy is not common, the discoveries have significant ...

(Date:12/16/2009)... could help ease health and environmental concerns about the ... for changing the behavior of nanoparticles in municipal sewage ... Their study was published in ACS, journal Environmental ... UK Centre for Ecology and Hydrology and colleagues note ... nanoparticles particles less than 1/1000th the width of ...

(Date:12/16/2009)... Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an Affordable ... ... Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy families ... all natural skin care for their children as Episencial ... featuring the beloved artwork of The Very Hungry Caterpillar from ...

(Date:12/16/2009)... caution, though, that no direct link has been found, ... bacteria in food -- commonly linked to food poisoning ... might also be the cause of some urinary tract ... the bacteria in chicken from stores and restaurants and ... evidence that the germs were transmitted directly to the ...

(Date:12/16/2009)... and MassBio promote Massachusetts companies through annual marketing campaign ... ... 2009 -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , , ,Genetown is sponsored by MassBio ... device industries. The campaign places each entity’s brand on an ...

Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2 Health News:Behavior modification could ease concerns about nanoparticles 2 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5 Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2 Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3 Health News:Thriving Bioscience Region Leaves Its Mark 2

[0] Leprosy Genes Identified [0] Behavior modification could ease concerns about nanoparticles [1] New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" [0] Foodborne E. Coli Suspected in Urinary Tract Infections [0] Thriving Bioscience Region Leaves Its Mark

... CHAPEL HILL, N.C., Sept. 13 "Profit, customers and,people ... the conference,Human Capital Management: Facing the Challenges of the ... taking care of your people, your people,will take care ... of your,business." At the recent HR-focused conference of ...

... now under development could enhance the design of sports ... sporting potential. , The models, more sophisticated and more ... produce unprecedentedly realistic simulations of how potential ball designs, ... , This data can then be harnessed by sports ...

... N.J., Sept. 12 The following is,a statement issued by ... CASSIDY, ON BEHALF OF ROSA ACUNA, RE: ... V. TURKISH, Today,s opinion is a stunning and surprising, ... Jersey. The opinion represents a,significant departure, in our judgment, from ...

... /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or the ... developing therapeutics for disease indications,with large markets, ... year,ended June 30, 2007. Selected Highlights ... up to the date of this press ...

... EPI-Q, a leading healthcare,management consulting firm, announces today ... key appointment. EPI-Q, Inc. specializes in assisting life,sciences ... outcomes,and cost-effectiveness of patient care. Andrew Baker ... NY. Mr. Baker will have responsibility for global ...

... BEDFORD, Mass., Sept. 12 Hologic, ... of state-of-the-art diagnostic and,digital imaging systems directed ... statement, including a joint proxy,statement/prospectus, for a ... ), has become effective. The Company will ...

Broker a Suite of Research & Advisory Services to Enhance Human Resources Computer models help raise the bar for sporting achievement Historic Abortion Case; Acuna V. Turkish Transition Therapeutics Announces Fiscal 2007 Year End Financial Results EPI-Q Opens East Coast Office and Appoints Vice President-Business Development Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation

The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...

... precise requirements of blood banking and ... Equipment meets American Association of Blood ... (ANRC) and U.S. Food & Drug ... and platelet incubators feature alarm systems ...

Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....

TBR-120-1-GD is large capacity upright style refrigerator with an operating temperature of +4C. It is a specially designed refrigerator for the storage of blood in standard 500ml bags, complying with...

Medicine Products:

Blood Storage Refrigerator TBR-360-1-GD Blood Bank Refrigerator 3626 Blood Storage Refrigerator TBR-160-1-GD Blood Storage Refrigerator TBR-120-1-GD

( 6%) larynx (52%/36%) subcutaneoustis...)Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer,Health